Thank you, Mr. Chair.
Thank you to the presenters.
Mr. DeRochie, what I will say is more of a comment on my part. I like to think that I'm a positive person, so we'll agree on some things and disagree on others. When it comes to Trans Mountain, I strongly disagree with you. I think that Trans Mountain is certainly in our economic interest, in our national economic interest in particular, so I can't take what you said there.
With respect to carbon pricing, I'm glad you've put forward some imaginative ideas and answers to my colleague's question in particular. I think there's an emerged consensus—I was going to say “emerging”, but I would say it's an emerged consensus—on this issue. Even Preston Manning is behind the idea of putting in place a price on pollution and carbon pricing mechanisms, which I think is tremendously important. There are still some holdouts, unfortunately, but hopefully we'll get there.
Ms. Murray, I sympathize very much with what you said about multi-year funding. We have some outstanding researchers where I'm from in London, Ontario, working in our hospitals, researching stem cells in particular, so I support what you've brought to the table. It's a really important issue, to get that multi-year funding for organizations. Unfortunately, it can't happen every time because there are limited resources, but the examples you've brought with you that you stated at the outset were deeply moving, so thank you very much.
My question is for Mr. Mizzen.
In your comments, sir, you talked about pharmacare. You spoke about rare diseases. In London, Ontario, we have an outstanding organization, the Bethanys Hope Foundation, which has done incredible work in advancing the research around metachromatic leukodystrophy or MLD, an extremely rare disease. I wonder if you could just restate what you said about rare diseases. I just want to make sure that it's on the record.